Atlas Trials

Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome

Clinical trial NCT05126563 · COMPLETED

Trial details

NCT number
NCT05126563
Sponsor
Hope Biosciences Research Foundation
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Post COVID-19 Syndrome
Start date
2022-02-02
Primary completion
2024-04-02
Enrollment
79

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.